Sunteți pe pagina 1din 6

LPL - PSC SAROJ DIAGNOSTIC CENTRE 70/6, Yusuf Sarai Market, New Delhi – 110016, Ph :

011-41640132

Name

:

Baby DIYA ARAVIND

 

Collected

: 29/8/2015 12:01:00PM

 

Received

: 29/8/2015 12:01:10PM

Lab No.

:

222690169

Age:

7 Years

Gender:

Female

Reported

: 29/8/2015

5:32:52PM

A/c Status

:

P

Ref By :

aiims

Report Status

: Interim

Test Name

Results

Units

Bio. Ref. Interval

LIPID PROFILE, BASIC, SERUM

 

(Spectrophotometry, Calculated)

Cholesterol Total

 

273.00

mg/dL

<170.00

Triglycerides

388.00

mg/dL

<150.00

HDL Cholesterol

 

53.00

mg/dL

40.00 - 60.00

LDL Cholesterol

142.40

mg/dL

<110.00

VLDL Cholesterol

77.60

mg/dL

<30.00

Non-HDL Cholesterol

220.00

mg/dL

Interpretation

--------------------------------------------------------------------

|

NCEP

| TOTAL

| TRIGLYCERIDE | LDL CHOLESTEROL |

|

RECOMMENDATIONS

| CHOLESTEROL

| in mg/dL

| in mg/dL

|

|

| in mg/dL

|

|

|

|-------------------|---------------|--------------|-----------------|

| Optimal

|-------------------|---------------|--------------|-----------------|

| Borderline High

|

|

|-------------------|---------------|--------------|-----------------|

| High

|

|-------------------|---------------|--------------|-----------------|

| Very High

|

--------------------------------------------------------------------

| <170

| <150

| <110

| 171-199

| >=200

|

-

| 150-199

| 200-499

| >=500

| 111-129

| >=130

|

-

Note

1. Measurements in the same patient can show physiological & analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. NCEP identifies elevated Triglycerides as an independent risk factor for Coronary Heart Disease (CHD).

4. Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

5. ATP III guidelines uses LDL Cholesterol as the primary target for cholesterol lowering therapy. Note that major risk factors can modify LDL goals.

NON HDL CHOLESTEROL

-----------------------------------------------------------------------

| RISK CATEGORY

|----------------------|-------------------------|----------------------|

| NON HDL GOAL ( mg/dL)|

| LDL GOAL ( mg/dL)

| CHD & CHD risk

| < 100

| < 130

|

| equivalent (10 year |

|

|

| risk for CHD > 20 %) |

|

|

-----------------------------------------------------------------------

|----------------------|-------------------------|----------------------|

| Multiple (2+) Risk

|

| < 130

| < 160

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 4)

Page1of6

LPL - PSC SAROJ DIAGNOSTIC CENTRE 70/6, Yusuf Sarai Market, New Delhi – 110016, Ph :

011-41640132

Name

: Baby DIYA ARAVIND

Collected

: 29/8/2015 12:01:00PM

 

Received

: 29/8/2015 12:01:10PM

Lab No.

222690169

: Age:

7 Years

Gender:

Female

Reported

: 29/8/2015

5:32:52PM

A/c Status

: Ref By :

P

aiims

Report Status

: Interim

Test Name

Results

Units

Bio. Ref. Interval

| Factors and 10 year

|

|

|

| risk < or = 20%

|

|

|

|----------------------|-------------------------|----------------------|

|

-----------------------------------------------------------------------

| 0-1 Risk factor

| < 160

| <190

Comment:

ATP III suggested the addition of Non HDL Cholesterol (Total Cholesterol - HDL Cholesterol) as an indicator of all atherogenic lipoproteins ( Mainly LDL & VLDL). The Non HDL Cholesterol is used as a secondary target of therapy in persons with triglycerides >=200 mg/dL. The goal for Non HDL Cholesterol in those with increased triglyceride is 30 mg/dL above that set for LDL Cholesterol. For calculation of CHD risk, history of smoking, any medication for hypertension & current blood pressure levels are required.

PatientReportSCSuperPanel.GENERAL_PANEL_ANALYTE_SC (Version: 4)

Page2of6

LPL - PSC SAROJ DIAGNOSTIC CENTRE 70/6, Yusuf Sarai Market, New Delhi – 110016, Ph :

011-41640132

Name

:

Baby DIYA ARAVIND

 

Collected

: 29/8/2015 12:01:00PM

 

Received

: 29/8/2015 12:01:10PM

Lab No.

:

222690169

Age:

7 Years

Gender:

Female

Reported

: 29/8/2015

5:32:56PM

A/c Status

:

P

Ref By :

aiims

Report Status

: Interim

Test Name

 

Results

Units

Bio. Ref. Interval

CREATININE, 24-HOUR URINE

 

(Compensated Jaffe's reaction, IDMS traceable)

 

Creatinine, 24 Hour

 

9.10

mg/kg/day

8.00 - 22.00

Total Urine volume

750

mL/day

650.00 - 1000.00

Body weight

 

15

kg

PROTEIN, TOTAL, 24-HOUR URINE

 

(Spectrophotometry)

 

Total Protein

 

0.66

g/day

0.04 - 0.15

Total Urine Volume

 

750

mL/day

650.00 - 1000.00

Interpretation

 

-------------------------------------------

 

|

STATE

| RESULT IN g/day

|

|----------------|--------------------------|

| At rest

|

|----------------|--------------------------|

|

| After exercise | <0.25

-------------------------------------------

| 0.04 - 0.15

Note

1. Excretion of total protein in individuals is highly variable with or without kidney disease.

2. Conditions affecting protein excretion other than kidney disease are urinary tract infection, diet, menstruation & physical activity

Comments

Diagnosis of kidney disease and response to therapy is usually obtained by quantitatively analyzing the amount of protein excreted in urine over a 24 hour period.

------------------------------------------------------------

| TYPES OF

| TOTAL PROTEIN IN | CONDITIONS

|

| PROTEINURIA | g /day

|

|

|-------------|------------------|---------------------------|

| Heavy

| Nephrotic syndrome, Acute |

| >4

| |

| Rapidly Progressive &

|

| |

| Chronic

|

| |

| Glomerulonephritis,

|

| |

| Diabetes mellitus, Lupus |

| |

| erythematosus, Drugs like |

| |

| Penicillamine, Heavy

|

| |

| metals like Gold & Mercury|

|-------------|------------------|---------------------------|

| Moderate

| Nephrosclerosis, Multiple |

| 1-4

| |

| myeloma, Toxic

|

| |

| nephropathies, Renal

|

| |

| calculi

|

|-------------|------------------|---------------------------|

| Minimal

| <1

| Chronic pyelonephritis,

|

| |

| Chronic interstitial

|

| |

| nephritis, Renal tubular

|

| |

| diseases, Postural

|

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 5)

Page3of6

LPL - PSC SAROJ DIAGNOSTIC CENTRE 70/6, Yusuf Sarai Market, New Delhi – 110016, Ph :

011-41640132

Name

: Baby DIYA ARAVIND

Collected

: 29/8/2015 12:01:00PM

 

Received

: 29/8/2015 12:01:10PM

Lab No.

222690169

: Age:

7 Years

Gender:

Female

Reported

: 29/8/2015

5:32:56PM

A/c Status

: Ref By :

P

aiims

Report Status

: Interim

Test Name

Results

Units

Bio. Ref. Interval

------------------------------------------------------------

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 5)

Page4of6

LPL - PSC SAROJ DIAGNOSTIC CENTRE 70/6, Yusuf Sarai Market, New Delhi – 110016, Ph :

011-41640132

Name

: Baby DIYA ARAVIND

Collected

: 29/8/2015 12:01:00PM

 

Received

: 29/8/2015 12:01:10PM

Lab No.

222690169

: Age:

7 Years

Gender:

Female

Reported

: 29/8/2015

5:33:01PM

A/c Status

: Ref By :

P

aiims

Report Status

: Interim

Test Name

Results

Units

Bio. Ref. Interval

HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD

4.70

%

(HPLC, NGSP certified)

Interpretation

-------------------------------------------------------------------------------

|

|-------------------------------------------------------------------------------|

| Reference Group

|

|

|-------------------------------|-----------------------------------------------|

|

|-------------------------------|-----------------------------------------------|

|

|-------------------------------|-----------------------------------------------|

|

| Diagnosing Diabetes

|-------------------------------|-----------------------------------------------|

| At risk (Prediabetes)

| Non diabetic adults >=18 years| <5.7

As per American Diabetes Association (ADA)

| HbA1c in %

| 5.7 - 6.4

| >= 6.5

|

Therapeutic goals for glycemic| Age > 19 years

|

|

control

| . Goal of therapy: < 7.0

|

|

| . Action suggested: > 8.0

|

|

|

|

|

| Age < 19 years

|

|

| . Goal of therapy: <7.5

|

-------------------------------------------------------------------------------

Note: 1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a

diabetic patient who is recently under good control may still have a high concentration of HbA1c. Converse is true for a diabetic previously under good control but now poorly controlled .

2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not be appropriate.

Comments

HbA1c provides an index of average blood glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

ADA criteria for correlation between HbA1c & Mean plasma glucose levels

---------------------------------------

| HbA1c(%) | Mean Plasma Glucose (mg/dL)|

|----------|----------------------------|

| 6

|

|----------|----------------------------|

| 7

|

|----------|----------------------------|

| 8

|

|----------|----------------------------|

| 9

|

| 126

| 154

| 183

| 212

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 5)

Page5of6

LPL - PSC SAROJ DIAGNOSTIC CENTRE 70/6, Yusuf Sarai Market, New Delhi – 110016, Ph :

011-41640132

Name

:

Baby DIYA ARAVIND

 

Lab No.

:

222690169

Age:

7 Years

Gender:

Female

A/c Status

:

P Ref By :

aiims

Collected

: 29/8/2015 12:01:00PM

Received

: 29/8/2015 12:01:10PM

Reported

: 29/8/2015

5:33:01PM

Report Status

: Interim

Test Name

Results

|----------|----------------------------|

|

|----------|----------------------------|

|

|----------|----------------------------|

|

| 12

| 11

| 10

| 240

| 269

| 298

---------------------------------------

10 | 240 | 269 | 298 --------------------------------------- Dr Onjal Taywade MD (Biochemistry) Consultant Biochemist

Dr Onjal Taywade MD (Biochemistry) Consultant Biochemist

Result/s to follow:

CD19

Consultant Biochemist Result/s to follow: CD19 Dr. Sushrut Pownikar DNB (Pathology) HOD Hemat & Imm

Dr. Sushrut Pownikar DNB (Pathology) HOD Hemat & Imm

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 5)

Units

Bio. Ref. Interval

Page6of6